Home » Abbott Confirms FDA Advisory Panel to Review Xience V Drug Eluting Stent on November 29
Abbott Confirms FDA Advisory Panel to Review Xience V Drug Eluting Stent on November 29
Abbott announced that the U.S. Food and Drug Administration (FDA) has confirmed a Circulatory Systems Devices Advisory Panel meeting on November 29, 2007, to review the company’s Premarket Approval (PMA) submission for the XIENCE V Everolimus Eluting Coronary Stent System.
Abbott
Upcoming Events
-
25Apr
-
07May
-
14May
-
30May